questionsmedicales.fr
Acides aminés, peptides et protéines
Protéines
Protéines et peptides de signalisation intracellulaire
Phosphatidylinositol 3-kinases
Phosphatidylinositol-4-phosphate 3-kinase
Phosphatidylinositol-4-phosphate 3-kinase : Questions médicales fréquentes
Termes MeSH sélectionnés :
Diagnostic
5
Kinases
Diagnostic médical
Tests de laboratoire
Phosphatidylinositols
Biopsie
Phosphatidylinositols
Symptômes
Phosphatidylinositols
Marqueurs biologiques
Phosphatidylinositols
Symptômes
5
Symptômes
Phosphatidylinositols
Troubles neurologiques
Phosphatidylinositols
Anomalies cutanées
Phosphatidylinositols
Douleurs articulaires
Phosphatidylinositols
Prévention
5
Prévention
Mode de vie sain
Dépistage
Tests génétiques
Habitudes alimentaires
Phosphatidylinositols
Exercice physique
Métabolisme
Facteurs environnementaux
Phosphatidylinositols
Traitements
5
Inhibiteurs
Traitement du cancer
Thérapie génique
Phosphatidylinositols
Effets secondaires
Inhibiteurs
Médecine personnalisée
Phosphatidylinositols
Complications
5
Complications
Phosphatidylinositols
Maladies cardiovasculaires
Phosphatidylinositols
Cancer
Phosphatidylinositols
Résistance aux traitements
Phosphatidylinositols
Troubles métaboliques
Phosphatidylinositols
Facteurs de risque
5
Facteurs de risque
Obésité
Âge
Phosphatidylinositols
Stress
Phosphatidylinositols
Antécédents familiaux
Phosphatidylinositols
Alimentation
Phosphatidylinositols
{
"@context": "https://schema.org",
"@graph": [
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol-4-phosphate 3-kinase : Questions médicales les plus fréquentes",
"headline": "Phosphatidylinositol-4-phosphate 3-kinase : Comprendre les symptômes, diagnostics et traitements",
"description": "Guide complet et accessible sur les Phosphatidylinositol-4-phosphate 3-kinase : explications, diagnostics, traitements et prévention. Information médicale validée destinée aux patients.",
"datePublished": "2024-06-02",
"dateModified": "2025-02-27",
"inLanguage": "fr",
"medicalAudience": [
{
"@type": "MedicalAudience",
"name": "Grand public",
"audienceType": "Patient",
"healthCondition": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol-4-phosphate 3-kinase"
},
"suggestedMinAge": 18,
"suggestedGender": "unisex"
},
{
"@type": "MedicalAudience",
"name": "Médecins",
"audienceType": "Physician",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "France"
}
},
{
"@type": "MedicalAudience",
"name": "Chercheurs",
"audienceType": "Researcher",
"geographicArea": {
"@type": "AdministrativeArea",
"name": "International"
}
}
],
"reviewedBy": {
"@type": "Person",
"name": "Dr Olivier Menir",
"jobTitle": "Expert en Médecine",
"description": "Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale",
"url": "/static/pages/docteur-olivier-menir.html",
"alumniOf": {
"@type": "EducationalOrganization",
"name": "Université Paris Descartes"
}
},
"isPartOf": {
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases",
"url": "https://questionsmedicales.fr/mesh/D019869",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases",
"code": {
"@type": "MedicalCode",
"code": "D019869",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556"
}
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases de classe I",
"alternateName": "Class I Phosphatidylinositol 3-Kinases",
"url": "https://questionsmedicales.fr/mesh/D058534",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases de classe I",
"code": {
"@type": "MedicalCode",
"code": "D058534",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.100"
}
},
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinase de classe Ia",
"alternateName": "Class Ia Phosphatidylinositol 3-Kinase",
"url": "https://questionsmedicales.fr/mesh/D058543",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinase de classe Ia",
"code": {
"@type": "MedicalCode",
"code": "D058543",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.100.100"
}
}
},
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases de classe Ib",
"alternateName": "Class Ib Phosphatidylinositol 3-Kinase",
"url": "https://questionsmedicales.fr/mesh/D058544",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases de classe Ib",
"code": {
"@type": "MedicalCode",
"code": "D058544",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.100.200"
}
}
}
]
},
{
"@type": "MedicalWebPage",
"name": "Phosphatidylinositol 3-kinases de classe II",
"alternateName": "Class II Phosphatidylinositol 3-Kinases",
"url": "https://questionsmedicales.fr/mesh/D058541",
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol 3-kinases de classe II",
"code": {
"@type": "MedicalCode",
"code": "D058541",
"codingSystem": "MeSH"
},
"identifier": {
"@type": "PropertyValue",
"propertyID": "MeSH Tree",
"value": "D12.776.476.556.200.200"
}
}
}
],
"about": {
"@type": "MedicalCondition",
"name": "Phosphatidylinositol-4-phosphate 3-kinase",
"alternateName": "Phosphatidylinositol-4-Phosphate 3-Kinase",
"code": {
"@type": "MedicalCode",
"code": "D058538",
"codingSystem": "MeSH"
}
},
"author": [
{
"@type": "Person",
"name": "Padinjat Raghu",
"url": "https://questionsmedicales.fr/author/Padinjat%20Raghu",
"affiliation": {
"@type": "Organization",
"name": "Cellular Organization and Signaling, National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore, 560065, India. Electronic address: praghu@ncbs.res.in."
}
},
{
"@type": "Person",
"name": "Swarna Mathre",
"url": "https://questionsmedicales.fr/author/Swarna%20Mathre",
"affiliation": {
"@type": "Organization",
"name": "National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India; Manipal Academy of Higher Education, Manipal, Karnataka 576104, India."
}
},
{
"@type": "Person",
"name": "Mariko Kato",
"url": "https://questionsmedicales.fr/author/Mariko%20Kato",
"affiliation": {
"@type": "Organization",
"name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan."
}
},
{
"@type": "Person",
"name": "Tomohiko Tsuge",
"url": "https://questionsmedicales.fr/author/Tomohiko%20Tsuge",
"affiliation": {
"@type": "Organization",
"name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan."
}
},
{
"@type": "Person",
"name": "Takashi Aoyama",
"url": "https://questionsmedicales.fr/author/Takashi%20Aoyama",
"affiliation": {
"@type": "Organization",
"name": "Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan."
}
}
],
"citation": [
{
"@type": "ScholarlyArticle",
"name": "'If we don't have consent, we need to have beneficence': Requiring beneficence in nonconsensual neurocorrection.",
"datePublished": "2022-05-19",
"url": "https://questionsmedicales.fr/article/35586936",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/bioe.13043"
}
},
{
"@type": "ScholarlyArticle",
"name": "The principle of procreative beneficence and its implications for genetic engineering.",
"datePublished": "2022-07-26",
"url": "https://questionsmedicales.fr/article/35882747",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s11017-022-09585-0"
}
},
{
"@type": "ScholarlyArticle",
"name": "From Monastic Benevolence to Medical Beneficence: The Inception of Medical Ethics in Wallachia and Moldavia before the Second Half of the 19th Century.",
"datePublished": "2022-08-17",
"url": "https://questionsmedicales.fr/article/36011864",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.3390/ijerph191610229"
}
},
{
"@type": "ScholarlyArticle",
"name": "Exploring the ethical complexity of pediatric organ transplant candidates and COVID-19 vaccination: Tensions between autonomy and beneficence, children and parents.",
"datePublished": "2022-10-09",
"url": "https://questionsmedicales.fr/article/36210480",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1111/petr.14408"
}
},
{
"@type": "ScholarlyArticle",
"name": "The All-Stakeholders-Considered Case for Corporate Beneficence.",
"datePublished": "2022-10-27",
"url": "https://questionsmedicales.fr/article/36320555",
"identifier": {
"@type": "PropertyValue",
"propertyID": "DOI",
"value": "10.1007/s10551-022-05224-9"
}
}
],
"breadcrumb": {
"@type": "BreadcrumbList",
"itemListElement": [
{
"@type": "ListItem",
"position": 1,
"name": "questionsmedicales.fr",
"item": "https://questionsmedicales.fr"
},
{
"@type": "ListItem",
"position": 2,
"name": "Acides aminés, peptides et protéines",
"item": "https://questionsmedicales.fr/mesh/D000602"
},
{
"@type": "ListItem",
"position": 3,
"name": "Protéines",
"item": "https://questionsmedicales.fr/mesh/D011506"
},
{
"@type": "ListItem",
"position": 4,
"name": "Protéines et peptides de signalisation intracellulaire",
"item": "https://questionsmedicales.fr/mesh/D047908"
},
{
"@type": "ListItem",
"position": 5,
"name": "Phosphatidylinositol 3-kinases",
"item": "https://questionsmedicales.fr/mesh/D019869"
},
{
"@type": "ListItem",
"position": 6,
"name": "Phosphatidylinositol-4-phosphate 3-kinase",
"item": "https://questionsmedicales.fr/mesh/D058538"
}
]
}
},
{
"@type": "MedicalWebPage",
"name": "Article complet : Phosphatidylinositol-4-phosphate 3-kinase - Questions et réponses",
"headline": "Questions et réponses médicales fréquentes sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Une compilation de questions et réponses structurées, validées par des experts médicaux.",
"datePublished": "2025-05-02",
"inLanguage": "fr",
"hasPart": [
{
"@type": "MedicalWebPage",
"name": "Diagnostic",
"headline": "Diagnostic sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Comment diagnostiquer une dysfonction de PI3K ?\nQuels tests sont utilisés pour évaluer PI3K ?\nLes biopsies sont-elles nécessaires pour le diagnostic ?\nQuels symptômes peuvent indiquer un problème avec PI3K ?\nY a-t-il des marqueurs spécifiques pour PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Beneficence#section-diagnostic"
},
{
"@type": "MedicalWebPage",
"name": "Symptômes",
"headline": "Symptômes sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quels sont les symptômes d'une activation anormale de PI3K ?\nComment PI3K affecte-t-il le métabolisme ?\nLes troubles neurologiques sont-ils liés à PI3K ?\nY a-t-il des signes cutanés associés à PI3K ?\nLes douleurs articulaires peuvent-elles être liées à PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Beneficence#section-symptômes"
},
{
"@type": "MedicalWebPage",
"name": "Prévention",
"headline": "Prévention sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Peut-on prévenir les troubles liés à PI3K ?\nY a-t-il des tests de dépistage pour PI3K ?\nLes habitudes alimentaires influencent-elles PI3K ?\nL'exercice physique aide-t-il à réguler PI3K ?\nLes facteurs environnementaux affectent-ils PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Beneficence#section-prévention"
},
{
"@type": "MedicalWebPage",
"name": "Traitements",
"headline": "Traitements sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quels traitements ciblent PI3K ?\nLes thérapies géniques peuvent-elles aider ?\nY a-t-il des effets secondaires des inhibiteurs de PI3K ?\nComment la nutrition influence-t-elle PI3K ?\nLes traitements sont-ils personnalisés pour PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Beneficence#section-traitements"
},
{
"@type": "MedicalWebPage",
"name": "Complications",
"headline": "Complications sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quelles complications peuvent survenir avec PI3K ?\nLes maladies cardiovasculaires sont-elles liées à PI3K ?\nComment PI3K influence-t-il le cancer ?\nY a-t-il des risques de résistance aux traitements ?\nLes troubles métaboliques sont-ils réversibles ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Beneficence#section-complications"
},
{
"@type": "MedicalWebPage",
"name": "Facteurs de risque",
"headline": "Facteurs de risque sur Phosphatidylinositol-4-phosphate 3-kinase",
"description": "Quels sont les facteurs de risque pour les troubles de PI3K ?\nL'âge influence-t-il le risque lié à PI3K ?\nLe stress a-t-il un impact sur PI3K ?\nLes antécédents familiaux jouent-ils un rôle ?\nL'alimentation influence-t-elle le risque de troubles de PI3K ?",
"url": "https://questionsmedicales.fr/mesh/D058538?mesh_terms=Beneficence#section-facteurs de risque"
}
]
},
{
"@type": "FAQPage",
"mainEntity": [
{
"@type": "Question",
"name": "Comment diagnostiquer une dysfonction de PI3K ?",
"position": 1,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques et des analyses biochimiques peuvent être utilisés pour diagnostiquer les anomalies de PI3K."
}
},
{
"@type": "Question",
"name": "Quels tests sont utilisés pour évaluer PI3K ?",
"position": 2,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les tests d'activité enzymatique et les dosages de métabolites spécifiques sont courants."
}
},
{
"@type": "Question",
"name": "Les biopsies sont-elles nécessaires pour le diagnostic ?",
"position": 3,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des biopsies peuvent être nécessaires pour évaluer l'expression de PI3K dans les tissus."
}
},
{
"@type": "Question",
"name": "Quels symptômes peuvent indiquer un problème avec PI3K ?",
"position": 4,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des symptômes variés comme des troubles métaboliques ou des anomalies de croissance peuvent survenir."
}
},
{
"@type": "Question",
"name": "Y a-t-il des marqueurs spécifiques pour PI3K ?",
"position": 5,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des marqueurs moléculaires comme PIK3CA peuvent indiquer une activation anormale de PI3K."
}
},
{
"@type": "Question",
"name": "Quels sont les symptômes d'une activation anormale de PI3K ?",
"position": 6,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les symptômes incluent des troubles métaboliques, des anomalies de croissance et des cancers."
}
},
{
"@type": "Question",
"name": "Comment PI3K affecte-t-il le métabolisme ?",
"position": 7,
"acceptedAnswer": {
"@type": "Answer",
"text": "PI3K régule le métabolisme en influençant la signalisation de l'insuline et la lipogenèse."
}
},
{
"@type": "Question",
"name": "Les troubles neurologiques sont-ils liés à PI3K ?",
"position": 8,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des dysfonctionnements de PI3K peuvent être associés à des troubles neurologiques."
}
},
{
"@type": "Question",
"name": "Y a-t-il des signes cutanés associés à PI3K ?",
"position": 9,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des anomalies cutanées peuvent apparaître, notamment dans des syndromes génétiques liés à PI3K."
}
},
{
"@type": "Question",
"name": "Les douleurs articulaires peuvent-elles être liées à PI3K ?",
"position": 10,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des troubles inflammatoires peuvent être exacerbés par des anomalies de PI3K."
}
},
{
"@type": "Question",
"name": "Peut-on prévenir les troubles liés à PI3K ?",
"position": 11,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation saine et un mode de vie actif peuvent réduire les risques associés à PI3K."
}
},
{
"@type": "Question",
"name": "Y a-t-il des tests de dépistage pour PI3K ?",
"position": 12,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des tests génétiques peuvent être recommandés pour les personnes à risque de troubles liés à PI3K."
}
},
{
"@type": "Question",
"name": "Les habitudes alimentaires influencent-elles PI3K ?",
"position": 13,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en acides gras oméga-3 peut moduler l'activité de PI3K."
}
},
{
"@type": "Question",
"name": "L'exercice physique aide-t-il à réguler PI3K ?",
"position": 14,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exercice régulier peut améliorer la signalisation de PI3K et la santé métabolique."
}
},
{
"@type": "Question",
"name": "Les facteurs environnementaux affectent-ils PI3K ?",
"position": 15,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, l'exposition à certains toxiques peut influencer l'activité de PI3K et le risque de maladies."
}
},
{
"@type": "Question",
"name": "Quels traitements ciblent PI3K ?",
"position": 16,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des inhibiteurs de PI3K sont utilisés dans le traitement de certains cancers et maladies métaboliques."
}
},
{
"@type": "Question",
"name": "Les thérapies géniques peuvent-elles aider ?",
"position": 17,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, la thérapie génique peut corriger des mutations dans les gènes codant pour PI3K."
}
},
{
"@type": "Question",
"name": "Y a-t-il des effets secondaires des inhibiteurs de PI3K ?",
"position": 18,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les effets secondaires peuvent inclure des troubles gastro-intestinaux et des infections."
}
},
{
"@type": "Question",
"name": "Comment la nutrition influence-t-elle PI3K ?",
"position": 19,
"acceptedAnswer": {
"@type": "Answer",
"text": "Une alimentation équilibrée peut moduler l'activité de PI3K et améliorer la santé métabolique."
}
},
{
"@type": "Question",
"name": "Les traitements sont-ils personnalisés pour PI3K ?",
"position": 20,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, les traitements peuvent être adaptés en fonction des mutations spécifiques de PI3K."
}
},
{
"@type": "Question",
"name": "Quelles complications peuvent survenir avec PI3K ?",
"position": 21,
"acceptedAnswer": {
"@type": "Answer",
"text": "Des complications incluent des cancers, des troubles métaboliques et des maladies cardiovasculaires."
}
},
{
"@type": "Question",
"name": "Les maladies cardiovasculaires sont-elles liées à PI3K ?",
"position": 22,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des anomalies de PI3K peuvent contribuer à des maladies cardiovasculaires par des mécanismes inflammatoires."
}
},
{
"@type": "Question",
"name": "Comment PI3K influence-t-il le cancer ?",
"position": 23,
"acceptedAnswer": {
"@type": "Answer",
"text": "PI3K est souvent activé dans divers cancers, favorisant la croissance tumorale et la survie cellulaire."
}
},
{
"@type": "Question",
"name": "Y a-t-il des risques de résistance aux traitements ?",
"position": 24,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des mutations dans PI3K peuvent entraîner une résistance aux inhibiteurs de PI3K."
}
},
{
"@type": "Question",
"name": "Les troubles métaboliques sont-ils réversibles ?",
"position": 25,
"acceptedAnswer": {
"@type": "Answer",
"text": "Certains troubles métaboliques liés à PI3K peuvent être gérés par des changements de mode de vie."
}
},
{
"@type": "Question",
"name": "Quels sont les facteurs de risque pour les troubles de PI3K ?",
"position": 26,
"acceptedAnswer": {
"@type": "Answer",
"text": "Les facteurs incluent des prédispositions génétiques, l'obésité et un mode de vie sédentaire."
}
},
{
"@type": "Question",
"name": "L'âge influence-t-il le risque lié à PI3K ?",
"position": 27,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le risque de troubles liés à PI3K augmente avec l'âge en raison de l'accumulation de mutations."
}
},
{
"@type": "Question",
"name": "Le stress a-t-il un impact sur PI3K ?",
"position": 28,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, le stress chronique peut affecter la signalisation de PI3K et contribuer à des maladies."
}
},
{
"@type": "Question",
"name": "Les antécédents familiaux jouent-ils un rôle ?",
"position": 29,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, des antécédents familiaux de cancers ou de troubles métaboliques augmentent le risque."
}
},
{
"@type": "Question",
"name": "L'alimentation influence-t-elle le risque de troubles de PI3K ?",
"position": 30,
"acceptedAnswer": {
"@type": "Answer",
"text": "Oui, une alimentation riche en sucres et graisses saturées peut augmenter le risque."
}
}
]
}
]
}
Expert en Médecine, Optimisation des Parcours de Soins et Révision Médicale
Validation scientifique effectuée le 27/02/2025
Contenu vérifié selon les dernières recommandations médicales
4 publications dans cette catégorie
Affiliations :
Cellular Organization and Signaling, National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore, 560065, India. Electronic address: praghu@ncbs.res.in.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India; Manipal Academy of Higher Education, Manipal, Karnataka 576104, India.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Institute for Chemical Research, Kyoto University, Gokasho, Uji, Kyoto, 611-0011 Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Section on Molecular Signal Transduction, Eunice Kennedy Shriver National Institute of Child Health and Human Development, National Institutes of Health, Bethesda, MD, USA ballat@mail.nih.gov.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Department of Biochemistry and Microbiology, University of Victoria, Victoria, British Columbia, Canada; Department of Biochemistry and Molecular Biology, The University of British Columbia, Vancouver, British Columbia, Canada.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Leibniz-Forschungsinstitut für Molekulare Pharmakologie (FMP), Berlin, Germany. haucke@fmp-berlin.de.
Departments of Biology, Chemistry, and Pharmacy, Freie Universität Berlin, Berlin, Germany. haucke@fmp-berlin.de.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular and Cell Biology and Biochemistry, Basic Veterinary Science, Faculty of Veterinary Medicine, Kagoshima University, Korimoto 1-21-24, Kagoshima 890-0065, Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular and Cell Biology and Biochemistry, Basic Veterinary Science, Faculty of Veterinary Medicine, Kagoshima University, Korimoto 1-21-24, Kagoshima 890-0065, Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular and Cell Biology and Biochemistry, Basic Veterinary Science, Faculty of Veterinary Medicine, Kagoshima University, Korimoto 1-21-24, Kagoshima 890-0065, Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Medical Research Institute, Tokyo Women's Medical University, 8-1 Kawada-cho, Shinjuku-ku, Tokyo 162-8666, Japan.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
3 publications dans cette catégorie
Affiliations :
Department of Molecular and Cell Biology and Biochemistry, Basic Veterinary Science, Faculty of Veterinary Medicine, Kagoshima University, Korimoto 1-21-24, Kagoshima 890-0065, Japan. Electronic address: afujita@vet.kagoshima-u.ac.jp.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
Sandra and Edward Meyer Cancer Center, Weill Cornell Medicine, New York, New York, USA.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
National Centre for Biological Sciences, TIFR-GKVK Campus, Bellary Road, Bangalore 560065, India.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
2 publications dans cette catégorie
Affiliations :
Department of Biochemistry, University of Toronto, ON, M5S 1A8, Toronto, Canada. greg.fairn@unityhealth.to.
Keenan Research Centre for Biomedical Sciences, St. Michael's Hospital, 209 Victoria Street, Toronto, ON, M5B 1T8, Canada. greg.fairn@unityhealth.to.
Department of Surgery, University of Toronto, Toronto, ON, M5T 1P5, Canada. greg.fairn@unityhealth.to.
Publications dans "Phosphatidylinositol-4-phosphate 3-kinase" :
Neurointerventions-interventions that cause direct physical, chemical or biological effects on the brain-are sometimes administered to criminal offenders for the purpose of reducing their recidivism r...
Molecular genetic engineering technologies such as CRISPR/Cas9 have made the accurate and safe genetic engineering of human embryos possible. Further advances in genomics have isolated genes that pred...
In Middle Ages, in Moldavia and Wallachia, the healthcare system was almost non-existent, medical practice being the attribute of old women, midwives, charmers, and later monastic personnel. The first...
POT is emotionally sensitive due to cohort vulnerability, their lack of decisional capacity, and waitlist mortality. The COVID-19 pandemic has added complexity to the setting of pediatric transplantat...
In the context of COVID-19 vaccination, two ethicists present four pediatric donation and transplant dilemmas for ethical exploration and offer guidance to clinical teams, noting that mandates are con...
As with all vaccinations, they are a tool of organ stewardship aimed to optimize outcomes and, in the setting of pediatrics, ensure optimal caregiving for these vulnerable recipients. Current evidence...
Our guidance considers the tensions of autonomy and beneficence and the ethical duty of organ stewardship. The harms of being unvaccinated and risking the harms of COVID-19 and long-COVID post-transpl...
In ways accentuated by the global coronavirus pandemic, corporations constitute vital instruments of the acts of beneficence needed by the people of the world to make progress in public health and inc...
Nowadays, patients in Thailand have easier access to public health services, resulting in an increased number of patients undergoing surgery. Therefore, the Royal College of Anesthesiologists produces...
To investigate the working experience of nurse anesthetists with beneficence for patients....
This study employed qualitative research using in-depth interviews. The sample consisted of 33 nurse anesthetists who volunteered to participate in the research project with more than ten years of wor...
The working experience of nurse anesthetists with beneficence for patients involves communicating and listening with compassion, being considerate, knowledgeable, and standard operations, team communi...
Working experience of nurse anesthetists with beneficence for patients exists with communication and listening with compassion, being considerate, communicating and forwarding the patient's necessary ...
This commentary on the task force report addresses the complex issues involved in autonomy, beneficence, liberty, and consent, which are often in competition in this and many other treatment issues fo...
The patient's autonomy and well-being are sometimes seen as central to the ethical justification of voluntary euthanasia (VE) and physician-assisted suicide (PAS). While respecting the patient's wish ...
Ethics-based nursing practice can transform health care practices. As the biggest human capital in the health care system, nurses are obliged to follow ethical principles in this field. One of these e...
This integrative review was conducted using the Whittemore & Knafl method in 5 stages, including problem identification, searching the literature, evaluating primary sources, analyzing data, and prese...
After reviewing and evaluating the qualified articles, the findings were classified into four main categories: (1) nature, (2) applicability, (3) Relevant and influential factors, and (4) challenges r...
Based on the results of this review it seems that paying attention to clarification the principle of beneficence in nursing care can provide positive outcomes for patients to benefit from this princip...
Direct oral anticoagulants (DOACs) have recently proven their efficacy and safety, as primary and secondary prevention agents for thrombosis in cancer patients. We aimed to determine if DOACs might be...
We analysed a large multicentric cohort of MPN patients treated with rivaroxaban or apixaban after atrial fibrillation (AF) or thrombotic events....
We included 135 MPN patients with a median follow-up of 23.8 months since DOAC initiation. Twenty patients (14.8 %) developed 30 thrombotic events (28 arterial thromboses in 19 patients) for a global ...
DOACs seem effective in preventing venous thrombosis in MPN patients with AF or VTE. For these high-risk patients, low-dose DOACs exposed patients to more arterial thrombosis but fewer bleeding events...